Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes
| Status: | Completed |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 5/3/2014 |
| Start Date: | October 2013 |
| End Date: | March 2014 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 1b, Randomized, Double-Blind, Active Comparator Controlled, 3-Period, Cross-Over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of PF-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Study B1621019 will assess efficacy and safety of two different dosing regimens of an
investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients
with type 2 diabetes
investigational agent (PF-04937319) compared to an approved drug (sitagliptin) in patients
with type 2 diabetes
Inclusion Criteria:
- Patients with type 2 diabetes, on background metformin therapy either alone or with 1
other oral anti-diabetic agent (excluding Actos)
Exclusion Criteria:
- Patients with cardiovascular event within 6-months of screening
- Patients with diabetic complications
- Female subjects who are pregnant or planning to become pregnant
- Subjects with unstable medical conditions (eg, hypertension)
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials